PharmaEngine

PharmaEngine EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 8.27 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 35.11 % — a change of -76.46% (lower).

EBIT/Assets

8.27 %

YoY

-76.46%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of PharmaEngine is 2025 8.27 % . Operating Income to Assets Ratio (EBIT/Assets) of PharmaEngine was 2024 35.11 % . It decreases by -76.46% lower compared to the previous year.

The PharmaEngine EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
1.10 TWD
Jan 1, 2019
1.37 TWD
Jan 1, 2020
17.90 TWD
Jan 1, 2021
13.55 TWD
Jan 1, 2022
9.90 TWD
Jan 1, 2023
7.01 TWD
Jan 1, 2024
35.11 TWD
Jan 1, 2025
8.27 TWD
The PharmaEngine EBIT/Assets history
YEAREBIT/AssetsYoY
8.27 %-76.46%
35.11 %+400.83%
7.01 %-29.16%
9.90 %-26.94%
13.55 %-24.31%
17.90 %+1,209.92%
1.37 %+23.84%
1.10 %-92.60%
14.91 %-26.95%
20.41 %+101.95%
10.11 %+321.85%
2.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Operating Income to Assets Ratio (EBIT/Assets) of PharmaEngine is 8.27 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of PharmaEngine changed from 35.11 % to 8.27 %, representing a -76.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s PharmaEngine with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — PharmaEngine

All Key Metrics — PharmaEngine